NeoGenomics Inc (NEO) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.

Total Assets Chart for NeoGenomics Inc

NeoGenomics Inc (NEO) total assets for FY2025 were USD 1.4B, a -17.0% change from FY2024. NeoGenomics Inc's total assets grew from USD 186.00 in 2000 to USD 1.4B in 2025 (731091297.8% over 25 years). Total assets compound annual growth rate: 5-year CAGR of 6.6%, 10-year CAGR of 14.0%, 20-year CAGR of 42.9%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$2.14B
Implied Share Price
$16.65
Enterprise Value
$2.66B
Revenue (TTM)
$766.29M
EBITDA
$24.32M
Profit Margin
-6.77%
Trailing P/E
—
Forward P/E
222.22
Price/Book (MRQ)
3.00
Price/Sales (TTM)
2.83
EV/EBITDA
197.32
EV/Revenue
3.47
Dividend Yield
—
Book Value
$6.14
Free Cash Flow (FY2025)
-$21.78M
Free Cash Flow Yield
-1.02%

Snapshot as of 18th October 2026 — not point-in-time controlled, may lag the live market by a few days.